A pharmaceutical composition for use in treatment or prevention of disorders caused by ischemia contains a mitochondrial damage inhibitor, an anti-inflammatory agent, and a biocompatible particle that encloses both or each of the above mitochondrial damage inhibitor and the above anti-inflammatory agent. The above-mentioned biocompatible particle may be a poly(lactic-co-glycolic acid) copolymer having a number mean particle size of 2.5 to 1000 nm or a polyethylene glycol modification thereof.
